Get the Stockscreener App
5.94
5.41%
-0.34
Pre-market:
5.99
0.05
+0.84%
Capricor Therapeutics Inc stock is traded at $5.94, with a volume of 2.00M.
It is down -5.41% in the last 24 hours and down -22.66% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$6.28
Open:
$6.32
24h Volume:
2.00M
Relative Volume:
0.82
Market Cap:
$271.56M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-7.1566
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-5.11%
1M Performance:
-22.66%
6M Performance:
-56.64%
1Y Performance:
+36.55%
1-Day Range:
$5.68
$6.32
1-Week Range:
$5.68
$6.43
52-Week Range:
$3.98
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
5.94 | 289.39M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Short interest data insights for Capricor Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - Newser
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Barchart.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
CAPR LAWSUIT ALERT: The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
What is the long term forecast for Capricor Therapeutics Inc. stock2025 Trading Recap & Verified Entry Point Signals - khodrobank.com
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investor Alert: Deadline in Lawsuit on September 15, 2025 - openPR.com
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR)Recover LossesContact Levi & Korsinsky Before September 15, 2025 - Barchart.com
Tools to assess Capricor Therapeutics Inc.’s risk profileMarket Growth Report & Growth Oriented Trade Recommendations - Newser
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - Morningstar
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week - Benzinga
Volatility clustering patterns for Capricor Therapeutics Inc.Market Volume Summary & Technical Pattern Alert System - Newser
Nuveen LLC Acquires Shares of 89,141 Capricor Therapeutics, Inc. $CAPR - Defense World
Long term hold vs stop loss in Capricor Therapeutics Inc.Weekly Profit Report & Expert Curated Trade Setup Alerts - Newser
Can Capricor Therapeutics Inc. disrupt its industryMarket Sentiment Summary & AI Powered Market Entry Ideas - khodrobank.com
Real time social sentiment graph for Capricor Therapeutics Inc.2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
מועד אחרון לתביעה נגד CAPR: רוזן, משרד עורכי דין מהימן ומוביל, מעודד משקיעים ב- Capricor Therapeutics, Inc. עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.
CAPR DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Chart based exit strategy for Capricor Therapeutics Inc.Earnings Growth Report & Free Community Consensus Stock Picks - Newser
How to forecast Capricor Therapeutics Inc. trends using time seriesJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - Morningstar
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER - GlobeNewswire
Market Overview: Can Capricor Therapeutics Inc. expand into new marketsJuly 2025 Macro Moves & Free Community Consensus Stock Picks - khodrobank.com
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Capricor Therapeutics, Inc. $CAPR Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Will Capricor Therapeutics Inc. outperform the marketJuly 2025 Price Swings & Verified Entry Point Signals - Newser
Detecting support and resistance levels for Capricor Therapeutics Inc.July 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CAPR Lawsuit Alert! Class Action Lawsuit Against Capricor Therapeutics - TipRanks
Combining machine learning predictions for Capricor Therapeutics Inc.Portfolio Risk Summary & Real-Time Market Sentiment Reports - Newser
Capricor Therapeutics Faces Challenges Despite Strong Cash Position - TipRanks
Multi factor analysis applied to Capricor Therapeutics Inc.July 2025 Catalysts & Entry and Exit Point Strategies - Newser
CAPR DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Deutsche Bank AG Has $272,000 Position in Capricor Therapeutics, Inc. $CAPR - Defense World
Vanguard Group Inc. Reduces Stock Holdings in Capricor Therapeutics, Inc. $CAPR - Defense World
Is Capricor Therapeutics Inc. forming a bottoming baseJobs Report & Fast Entry Momentum Trade Alerts - Newser
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion. - GlobeNewswire
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Morningstar
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):